CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar
CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →
Read More →Amgen buying rights to Advaxis cancer treatment
Thousand Oaks-based biotech giant Amgen said it will buy the rights to develop and commercialize a cancer immunotherapy treatment Aug. 2. Under the agreement, Amgen will pay Princeton, N.J.-based Advaxis $40 million and buy $25 million worth of Advaxis common stock for the rights to develop and commercialize a preclinical cancer immunotherapy, which is designed Read More →
Read More →
Pacific Coast Business Times stock index yields big return
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen reports revenue increase in second quarter earnings
Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →
Read More →Amgen settles lawsuit, says biosimilar works as well as Herceptin
Amgen settled a lawsuit and released positive news about a breast cancer biosimilar this week. The Thousand Oaks-based biotech giant said July 20 the company reached a settlement stemming from a class action lawsuit involving shareholders who sued the company over shares bought from the company between April 22, 2004 and May 10, 2007. Amgen Read More →
Read More →FDA declines to approve Novartis biosimilar for Amgen’s Neulasta
The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →
Read More →Thousand Oaks city manager’s firing won’t hinder economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
